Valuation : CRISPR Therapeutics AG

Market Cap 5.58B 4.81B 4.51B 4.12B 7.75B 533B 7.78B 53.5B 20.87B 269B 20.95B 20.5B 893B P/E 2026 *
-13.2x
P/E 2027 * -18.4x
Enterprise Value 4.13B 3.56B 3.34B 3.05B 5.75B 395B 5.76B 39.64B 15.46B 199B 15.52B 15.19B 661B EV / Sales 2026 *
101x
EV / Sales 2027 * 29.4x
Free-Float
94.01%
Yield 2026 *
-
Yield 2027 * -
1 day-2.78%
1 week-2.99%
Current month+20.28%
1 month+21.16%
3 months+2.74%
6 months-4.02%
Current year+10.07%
1 week 56.62
Extreme 56.62
61.55
1 month 47.31
Extreme 47.3101
62.54
Current year 44.12
Extreme 44.12
63.45
1 year 44.12
Extreme 44.12
78.48
3 years 30.04
Extreme 30.04
91.1
5 years 30.04
Extreme 30.04
129.5
10 years 11.63
Extreme 11.63
220.2
Manager TitleAgeSince
Chief Executive Officer 47 2017-11-30
Director of Finance/CFO 42 2023-03-13
Chief Tech/Sci/R&D Officer - 2024-05-27
Director TitleAgeSince
Director/Board Member 49 2015-04-28
Director/Board Member 49 2015-03-31
Chairman 47 2023-09-14
Date Insider Type Main position Quantity % Market Cap.
8/7/26 Don

Chief Financial Officer

-750 0.0008%
6/5/26
GSK Equity Investments Ltd.
FreeCompany 13,000 0.0135%
5/29/26 Sell

Chief Technology Officer

-3,786 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
-2.78%-2.99%+11.36%+14.14% 5.58B
-0.78%-1.42%+2.96%+21.65% 50.47B
-6.00%-0.75%+447.48%+535.14% 44.56B
-0.24%+0.74%+37.18%+16.26% 43.08B
-1.55%-2.07%+19.83%+71.70% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.79%-3.24%+26.32%+125.06% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.63%+27.62% 14.58B
-1.66%-1.25%+78.49%+42.97% 13.92B
Average -1.66%-1.25%+72.75%+100.31% 28.01B
Weighted average by Cap. -1.72%-1.10%+94.48%+126.60%

Financials

2026 *2027 *
Net sales 40.83M 35.18M 32.99M 30.11M 56.73M 3.9B 56.91M 391M 153M 1.97B 153M 150M 6.53B 157M 135M 127M 115M 218M 14.97B 218M 1.5B 586M 7.55B 588M 575M 25.05B
Net income -432M -373M -349M -319M -601M -41.33B -603M -4.14B -1.62B -20.86B -1.62B -1.59B -69.17B -351M -303M -284M -259M -488M -33.59B -490M -3.37B -1.31B -16.96B -1.32B -1.29B -56.22B
Net Debt -1.45B -1.25B -1.17B -1.07B -2.01B -138B -2.02B -13.86B -5.41B -69.77B -5.43B -5.31B -231B -980M -844M -792M -723M -1.36B -93.64B -1.37B -9.39B -3.66B -47.27B -3.68B -3.6B -157B
Logo CRISPR Therapeutics AG
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Employees
393
Date Price Change Volume
26-08-28 US$57.72 -2.78% 1,388,793
26-08-27 US$59.37 +0.24% 1,188,519
26-08-26 US$59.23 -2.74% 959,931
26-08-25 US$60.90 +6.70% 2,083,671
26-08-24 US$57.08 -4.08% 1,119,658
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
57.72USD
Average target price
87.56USD
Spread / Average Target
+51.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRSP Stock